高级检索
当前位置: 首页 > 详情页

Role of repeat transurethral resection in no-muscle-invasive bladder tumour: an umbrella review

文献详情

资源类型:
Pubmed体系:
机构: [1]Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ning 685 East Section of Huancheng North Road, Ningbo City, Zhejiang Province 315211, China. [2]Department of Pathology, Ningbo Medical Centre Lihuili Hospital, Ningbo City, Zhejiang Province, 315040, China. [3]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China. [4]Department of Urological Surgery, Daping Hospital, Army Medical Center of PLA, Army Medical University, Chongqing, China. [5]Cedars-Sinai Medical Center, Los Angeles, CA, USA. [6]Department of Urology, Kyung Hee University, Seoul, Republic of Korea. [7]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan Province 610041, China. [8]Division of Surgery &amp [9] Interventional Science, University College London, London, UK. [9]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan Province, 610041, China.
出处:
ISSN:

关键词: bladder cancer en-bloc resection of bladder tumour repeat transurethral resection of bladder tumour umbrella review

摘要:
Repeat transurethral resection of bladder tumour (reTURB) is a conventional treatment for non-muscle-invasive bladder cancer (NMIBC) to enhance prognosis. However, the necessity of reTURB in NMIBC remains controversial owing to upstaging of treatments and new evidence.We performed an umbrella review to determine the need for reTURB in patients with NMIBC.We extracted data from meta-analyses that were screened out after a systematic search of PubMed, Embase, the Web of Science and the Cochrane Database of Systematic Reviews.Risk of Bias in Systematic Reviews and the Grading of Recommendations, Assessment, Development and Evaluation tools were used to assess the quality of each included meta-analysis and outcomes.Our study included seven meta-analyses. Two studies assessed the efficiency of reTURB in patients who underwent en bloc resection of bladder tumours (ERBT). Patients who underwent ERBT reported low residual tumour and upstaging rates of 5.9% and 0.3%, respectively. Conversely, patients who underwent conventional transurethral resection for bladder cancer (cTURB) had high residual tumour rates. Patients who underwent cTURB and reTURB had significantly improved 1-year recurrence-free survival (RFS) compared to those who underwent initial cTURB alone. In terms of progression-free survival (PFS), a meta-analysis reported that patients who underwent cTURB and reTURB had significantly improved PFS compared with those who underwent initial cTURB alone. In the subgroup analyses of ERBT, reTURB did not affect the RFS and PFS of patients who received ERBT. Currently, only a limited number of randomised clinical trials have evaluated reTURB, and various factors have influenced its efficacy.There was significant variation in survival outcomes among patients undergoing reTURB. The necessity and efficacy of reTURB depend on numerous factors, such as surgical approach, equipment and medication usage. Patients eligible for ERBT may constitute a group that does not require reTURB. Further clinical trials are required to validate these findings.This umbrella review was registered with the International Prospective Register of Systematic Reviews (CRD42023439078).© The Author(s), 2024.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 3 区 肿瘤学
第一作者:
第一作者机构: [1]Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ning 685 East Section of Huancheng North Road, Ningbo City, Zhejiang Province 315211, China. [2]Department of Pathology, Ningbo Medical Centre Lihuili Hospital, Ningbo City, Zhejiang Province, 315040, China.
共同第一作者:
通讯作者:
通讯机构: [1]Department of Pathology, Ningbo Clinical Pathology Diagnosis Center, Ning 685 East Section of Huancheng North Road, Ningbo City, Zhejiang Province 315211, China. [2]Department of Pathology, Ningbo Medical Centre Lihuili Hospital, Ningbo City, Zhejiang Province, 315040, China. [7]Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Guoxue Xiang #37, Chengdu, Sichuan Province 610041, China. [8]Division of Surgery &amp
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:59238 今日访问量:0 总访问量:4856 更新日期:2025-06-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号